Health care utilization and mortality among elderly patients with myelodysplastic syndromes

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1181-1188

  Lindquist, K J ^a   Danese, M D ^a   Mikhael, J ^b   Knopf, K B ^c   Griffiths, R I ^a,d  

^a Outcomes Insights Inc   (United States)

^b MAYO CLINIC   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anemia; health services research; mortality; myelodysplastic syndromes; neutropenia; thrombocytopenia

Indexed keywords

AGED; ANEMIA; ARTICLE; FEMALE; HEALTH CARE DELIVERY; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MALE; MORTALITY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PREVALENCE; PROPORTIONAL HAZARDS MODEL; STATISTICS; THROMBOCYTOPENIA; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; ANEMIA; DELIVERY OF HEALTH CARE; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; PREVALENCE; PROPORTIONAL HAZARDS MODELS; THROMBOCYTOPENIA;

EID: 79961232055     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq552     Document Type: Article

References (34)

1. Langston, A.A., Walling, R., Winton, E.F., Update on myelodysplastic syndromes: new approaches to classification and therapy. Semin Oncol 31:2 (2004), 72–79.
2. National Comprehensive Cancer Network, Inc, The NCCN Clinical Practice Guidelines in Oncology™ Myelodsyplastic Syndromes. 2007, National Comprehensive Cancer Network, Inc., Fort Washington, PA (02 February 2008, date last accessed) http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
3. Aul, C., Gattermann, N., Schneider, W., Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:2 (1992), 358–367.
4. Cazzola, M., Malcovati, L., Myelodysplastic syndromes—coping with ineffective hematopoiesis. N Engl J Med 352:6 (2005), 536–538.
5. Maynadié, M., Verret, C., Moskovtchenko, P., et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 74:2 (1996), 288–290.
6. Horner, M.J., Ries, L.A.G., Krapcho, M., et al. SEER Cancer Statistics Review, 1975–2006. 2009, National Cancer Institute, Bethesda, MD (23 May 2009, date last accessed) http://seer.cancer.gov/csr/1975_2006.
7. Dansey, R., Myelodysplasia. Curr Opin Oncol 12:1 (2000), 13–21.
8. Blinder, V.S., Roboz, G.J., Hematopoietic growth factors in myelodysplastic syndromes. Curr Hematol Rep 2:6 (2003), 453–458.
9. List, A.F., Vardiman, J., Issa, J.P., et al. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 1 (2004), 297–317.
10. Warren, J.L., Klabunde, C.N., Schrag, D., et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:8 (2002), IV-3–IV-18.
11. Surveillance Epidemiology and End Results, SEER Data, 1973–2006. 2007, Surveillance Research Program, National Cancer Institute, Bethesda, MD (23 February 2007, date last accessed) http://seer.cancer.gov/data.
12. National Cancer Institute, SEER-Medicare: How the SEER & Medicare Data Are Linked. 2007, National Cancer Institute, Bethesda, MD (23 February 2007, date last accessed) http://healthservices.cancer.gov/seermedicare/overview/linked.html.
13. Harris, N.L., Jaffe, E.S., Diebold, J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:12 (1999), 3835–3849.
14. Bennett, J.M., World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72:2 (2000), 131–133 Review.
15. Vardiman, J.W., Harris, N.L., Brunning, R.D., The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 101:7 (2003), 2895–2896.
16. Charlson, M.E., Pompei, P., Ales, K.L., et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:5 (1987), 373–383.
17. Deyo, R.A., Cherkin, D.C., Ciol, M.A., Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:6 (1992), 613–619.
18. Romano, P.S., Roos, L.L., Luft, H.S., et al. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol 47:3 (1994), 249–260.
19. Young, J.L. Jr, Roffers, S.D., Ries, L.A.G., et al. SEER Summary Staging Manual—2000: Codes and Coding Instructions. 2001, National Cancer Institute, Bethesda, MD Pub. No. 01-4969. 2001;(23 February 2007, date last accessed) http://seer.cancer.gov/tools/ssm/.
20. Ma, X., Does, M., Raza, A., et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:8 (2007), 1536–1542.
21. Rollison, D.E., Howlader, N., Smith, M.T., et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112:1 (2008), 45–52.
22. Kantarjian, H., Giles, F., List, A., et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 109:9 (2007), 1705–1714.
23. Dayyani, F., Conley, A.P., Strom, S.S., et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 116:9 (2010), 2174–2179.
24. Goldberg, S.L., Chen, E., Corral, M., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 28:17 (2010), 2847–2852.
25. Mufti, G.J., Chen, T.L., Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 15:Suppl (2008), 14–28.
26. List, A.F., Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control 15:Suppl (2008), 29–39.
27. Sekeres, M.A., Schoonen, M., Kantarjian, H., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 100:21 (2008), 1542–1551.
28. Gore, S.D., Hermes-DeSantis, E.R., Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 15:Suppl (2008), 40–49.
29. Malcovati, L., Germing, U., Kuendgen, A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:23 (2007), 3503–3551.
30. Wang, R., Gross, C.P., Halene, S., et al. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33:12 (2009), 1594–1598.
31. KD Kochanek BL Smith. Deaths: Preliminary Data for 2002. National Vital Statistics Report Vol. 52, no. 13. Hyattsville, Maryland: National Center for Health Statistics 2004.
32. De Roos, A.J., Deeg, H.J., Davis, S., A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 18:10 (2007), 1199–1208.
33. Cheson, B.D., Bennett, J.M., Kantarjian, H., et al. World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:12 (2000), 3671–3674.
34. Steensma, D.P., Tefferi, A., The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 27:2 (2003), 95–120.